The association between response to TKI treatment and demographic and clinicopathological characteristics from TKI‐treated NSCLC patients harboring EGFR‐sensitizing mutations (n = 111) was also assessed, and no association was revealed (Table S1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.